Back to Search
Start Over
Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
- Source :
- Blood. 140:10140-10141
- Publication Year :
- 2022
- Publisher :
- American Society of Hematology, 2022.
- Subjects :
- Immunology
Cell Biology
Hematology
Biochemistry
Subjects
Details
- ISSN :
- 15280020 and 00064971
- Volume :
- 140
- Database :
- OpenAIRE
- Journal :
- Blood
- Accession number :
- edsair.doi...........45b0ed2730650e2f9341b7e5ed3ea2ab
- Full Text :
- https://doi.org/10.1182/blood-2022-159969